Bioventus (BVS) Stock Price, News & Analysis

Company Overview

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions. In the arena of joint health, Bioventus markets hyaluronic acid‐based injectables, notably DUROLANE®, as well as cold therapy devices under its QUELL® and HEALICOOL® brands to support post-surgical and non-surgical rehabilitation.

Founded in 2012 as a spin-out from Smith & Nephew, Bioventus has expanded its global footprint through strategic acquisitions and product launches. In 2020, the company completed the acquisition of Zimmer Biomet’s biologics business, bolstering its position in the spine and orthopedics markets. Bioventus now operates in more than 40 countries, with commercial activities spanning the United States, Europe, Asia-Pacific and Latin America. Its expansive distribution network and partnerships with hospital systems, orthopedic centers and sports medicine clinics support broad adoption of its non-operative treatment options.

Leadership at Bioventus is spearheaded by President and Chief Executive Officer Eric W. Martins, who joined the company in 2016 with extensive experience in the orthopedic and pharmaceutical industries. He leads a management team focused on driving innovation, expanding clinical evidence and enhancing patient access to orthobiologic therapies. Under this leadership, Bioventus continues to invest in research and development, aiming to introduce new products and strengthen its position as a leader in the non-surgical musculoskeletal market.

Key Stats

• Today's Range: $13.00 to $13.59
• 50-Day Range: $7.93 to $13.47
• 52-Week Range: $5.81 to $14.00
• Volume: 946,990 shs
• Average Volume: 696,733 shs
• Market Capitalization: $1.12 billion
• P/E Ratio: 32.73
• Dividend Yield: N/A
• Price Target: $14.75
• Consensus Rating: Buy

Bioventus Stock Analysis - MarketRank™

Bioventus scored higher than 69% of companies evaluated by MarketBeat, and ranked 151st out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Buy

Consensus Rating

Bioventus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and no sell ratings.

Upside/Downside

The consensus price target for Bioventus is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Bioventus has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.66%

Earnings Growth

Earnings for Bioventus are expected to grow by 12.66% in the coming year, from $0.79 to $0.89 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bioventus is 32.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.40.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bioventus is 32.73, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 279.14.

Price to Earnings Growth Ratio

Bioventus has a PEG Ratio of 1.72. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bioventus has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.91% of the float of Bioventus has been sold short.

Short Interest Ratio / Days to Cover

Bioventus has a short interest ratio ("days to cover") of 3.54, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bioventus has recently increased by 24.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bioventus does not currently pay a dividend.

Dividend Growth

Bioventus does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.33

News Sentiment

Bioventus has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Bioventus this week, compared to 2 articles on an average week.

Search Interest

17 people have searched for BVS on MarketBeat in the last 30 days. This is an increase of 325% compared to the previous 30 days.

MarketBeat Follows

15 people have added Bioventus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bioventus insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.50% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/04/2025
• Today: 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BVS
• Previous Symbol: NASDAQ:BVS
• CIK: 1665988
• Web: N/A
• Phone: (919) 474-6700
• Fax: N/A
• Employees: 1,200
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Bioventus: $14.75
• High Price Target: $16.00
• Low Price Target: $14.00
• Potential Upside/Downside: +9.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.41
• Trailing P/E Ratio: 32.73
• Forward P/E Ratio: 16.99
• P/E Growth: 1.72
• Net Income: $22.73 million
• Net Margins: 4.94%
• Pretax Margin: 5.84%
• Return on Equity: 29.97%
• Return on Assets: 9.52%

Debt

• Debt-to-Equity Ratio: 1.08
• Current Ratio: 1.69
• Quick Ratio: 1.13

Sales & Book Value

• Annual Sales: $576.30 million
• Price / Sales: 1.95
• Cash Flow: $1.27 per share
• Price / Cash Flow: 10.56
• Book Value: $2.76 per share
• Price / Book: 4.86

Miscellaneous

• Outstanding Shares: 83,535,000
• Free Float: 55,551,000
• Market Cap: $1.12 billion
• Optionable: N/A
• Beta: 0.63